Pharmaceutical Major Lupin has entered into an agreement to acquire the balance 40% equity stake in South African generics major, Pharma Dynamics(PD) from its founders. As per the agreement, the founders will exercise their put option before March 31,2015, for the 40% equity stake it currently holds. On completion of this transaction, PD will become a wholly owned subsidiary of Lupin.
About three years ago, Betty Vaughn of Golden Valley, Minn., started to feel light-headed, fatigued and out of breath when she walked up and down the stairs. After visiting her doctor, the 89-year-old was diagnosed with degenerative mitral regurgitation (DMR), a heart condition in which the leaflets of the mitral valve do not close completely, causing blood to flow backward and leak into the left atrium of the heart.
Mylan N.V. and Mylan Inc. announced the U.S. launch of Buprenorphine Hydrochloride Sublingual Tablets (2 mg and 8 mg) and Disulfiram Tablets USP (250 mg and 500 mg) which are the generic versions of Reckitt Benckiser's Subutex® Sublingual Tablets and Odyssey Pharmaceutical's Antabuse® respectively.
[adsense:336x280:8701650588]
(Business Wire India); Kiran Mazumdar-Shaw, Chairperson of Asia's premier biopharmaceutical enterprise Biocon Ltd., has been honoured by Federation University Australia (Fed Uni) by dedicating a road at the University’s Mt Helen Campus to her as ‘Mazumdar Drive’. She has also been appointed as an Ambassador of the University for a three-year term.
[adsense:336x280:8701650588]
A Pharmaceutical exporter, Chemfar Organics, establishing ultra modern manufacturing facility for tablets & capsules around Bengaluru, inviting partners for share participation.
GlaxoSmithKline (GSK) and Sun Pharmaceutical Industries Ltd. (Sun Pharma) announced that their respective wholly owned subsidiaries have reached an agreement related to GSK’s Opiates business in Australia.
Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) got approval from EU for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older.
GlaxoSmithKline plc (GSK) announces that its three-part transaction with Novartis has completed today. As a result of this transaction, GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines) for an initial cash consideration of $5.25 billion; has created a new world-leading Consumer Healthcare joint venture with Novartis in which GSK will have majority control and an equity interest of 63.5%; and has divested its Oncology business for an aggregate cash consideration of $16 billion.
-- Major European markets can finally benefit from the availability of Inflectra following the patent expiry of reference product Remicade® (infliximab)
-- Inflectra provides an alternative, potentially more affordable treatment option for people suffering from severe, debilitating diseases such as rheumatoid arthritis and inflammatory bowel disease while maintaining comparable quality, efficacy and safety to the reference product
GSK has acquired GlycoVaxyn AG, a specialist vaccine biopharmaceutical company based in Switzerland and seems to stregthen their vaccine pipeline. Since forming a scientific collaboration in 2012, GSK has held a minority stake in GlycoVaxyn and has now acquired the remaining shares for US $190 million (approximately £124 million) in cash to take full ownership of the company.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
